


Form PTO-1449 (REV. 1/06) US Dept. of Commerce PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			ATTY DOCKET NO. 128186	APPLICATION NO. 10/580,532
			APPLICANTS Taiji FURUKAWA et al.	
			FILING DATE May 25, 2006	



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Name	
	1	4,576,934	3/18/1986	Seto et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation
	2	WO 03/062201 A1	7/31/2003	WIPO		
	3	EP 230 944 A1	8/5/1987	Europe		
	4	JP A 1-275591	11/6/1989	Japan	X	
	5	WO 2004/024153	3/25/2004	WIPO		
	6	JP A 60-69089	4/19/1985	Japan	X	
	7	JP A 63-233992	9/29/1988	Japan	X	
	8	JP A 61-030591	2/12/1986	Japan	X	
	9	JP A 61-063688	4/1/1986	Japan	X	
	10	JP A 62-169795	7/25/1987	Japan	X	
	11	JP A 62-169796	7/25/1987	Japan	X	
	12	JP A 58-167569	10/3/1983	Japan	X	
	13	JP A 55-000301	1/5/1980	Japan	X	
	14	JP A 62-174017	7/30/1987	Japan	X	
	15	JP A 60-097956	5/31/1985	Japan	X	
	16	JP A 49-108082	10/14/1974	Japan	X	
	17	JP A 2-138221	5/28/1990	Japan	X	
	18	JP A 2002-226376	8/14/2002	Japan	X	X

OTHER DOCUMENTS

Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER	DATE CONSIDERED
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Rev. 1/06)			US Dept. of Commerce PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY DOCKET NO. 128186		APPLICATION NO. 10/580,532	
					APPLICANTS Taiji FURUKAWA et al.			
					FILING DATE May 25, 2006			
U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number	Date	Name				
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation		
OTHER DOCUMENTS								
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)						
	19	K. HARADA et al.; "Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities - Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variables and ¹²³ I-Metaiodobenzylguanidine Myocardial Scintigraphy;" <i>Circulation Journal</i> , Vol. 67, February 2003, pp. 139-145.						
	20	P. KUMAR et al.; "Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity;" <i>Molecular Pharmacology</i> , 2002, Vol. 61, No. 3, pp. 649-658.						
	21	H. SUZUKI et al.; "Antihypertensive Effects and Reducing Effects on Proteinuria of Cilnidipine on Hypertension Patients with Nephrosclerosis;" <i>Therapeutic Research</i> , 2000, Vol. 21, No. 4, pp. 760-762.						
	22	D. BILICI et al.; "Protective Effect of T-Type Calcium Channel Blocker in Histamine-Induced Paw Inflammation in Rat;" <i>Pharmacological Research</i> , 2001, Vol. 44, No. 6, pp. 527-531.						
	23	C. BAYLIS et al.; "Comparison of L-Type and Mixed L- and T-Type Calcium Channel Blockers on Kidney Injury Caused by Deoxycorticosterone-Salt Hypertension in Rats;" <i>American Journal of Kidney Diseases</i> , 2001, Vol. 38, No. 6, pp. 1292-1297.						
	24	W. MCCALMONT et al.; "Design, Synthesis, and Biological Evaluation of Novel T-Type Calcium Channel Antagonists;" <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, Vol. 14, No. 14, pp. 3691-3695.						
	25	D. PORCELLO; "Actions of U-92032, a Type Ca ²⁺ Channel Antagonist, Support a Functional Linkage Between <i>I_h</i> and Slow Intrathalamic Rhythms;" <i>J Neurophysiol.</i> , 2003, Vol. 89, No. 1, pp. 177-185.						
	26	H. MASUMIYA et al.; "Effects of Ca ²⁺ channel antagonists on sinus node: Prolongation of late phase 4 depolarization by efonidipine"; <i>European Journal of Pharmacology</i> ; Vol. 335; 1997; pp. 15-21.						
	27	P. MULDER et al.; "Increased Survival After Long-Term Treatment with Mibeprafil, a Selective T-Channel Calcium Antagonist, in Heart Failure"; <i>JACC</i> ; Vol. 29, No. 2; February 1997; pp. 416-421.						
	28	J. VILLAME et al.; "Effects of Mibeprafil, a T- and L-Type Calcium Channel Blocker, on Cardiac Remodeling in the UM-X7.1 Cardiomyopathic Hamster"; <i>Cardiovascular Drugs and Therapy</i> ; Vol. 15; 2001; pp. 41-48.						
	29	S. FAREH et al.; "The T-Type Ca ²⁺ Channel Blocker Mibeprafil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs"; <i>Circulation</i> ; Vol. 100; November 23, 1999; pp. 2191-2197.						
EXAMINER						DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449 (Rev. 1/06)			US Dept. of Commerce PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY DOCKET NO. 128186		APPLICATION NO. 10/580,532	
					APPLICANTS Taiji FURUKAWA et al.			
					FILING DATE May 25, 2006			
U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number	Date	Name				
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation		
OTHER DOCUMENTS								
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)						
	30	G. NOLL et al.; "Comparative Pharmacological Properties among Calcium Channel Blockers: T-Channel versus L-Channel Blockade"; <i>Cardiology</i> ; Vol. 89; Supp. 1; 1998; pp. 10-15.						
	31	S. LENGLET et al.; "Activation of 5-HT ₇ Receptor in Rat Glomerulosa Cells is Associated with an Increase in Adenylyl Cyclase Activity and Calcium Influx through T-Type Calcium Channels"; <i>Endocrinology</i> ; Vol. 143, No. 5; pp. 1748-1760.						
	32	J. MCCALLUM et al.; "Loss of T-type Calcium Current in Sensory Neurons of Rats with Neuropathic Pain"; <i>Anesthesiology</i> ; Vol. 98, No. 1; 2003; pp. 209-216.						
EXAMINER /Emily Bernhardt/						DATE CONSIDERED 09/29/2009		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								